Structured evidence table for Plant Sterols Cholesterol Meta-Analysis, generated from 3 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Plant Sterols Cholesterol Meta-Analysis | Evidence from published experimental, clinical, and mechanistic investigations that were indexed in PubMed, Scopus, Web of Science, and Google Scholar between 2014 and 2025 is compiled in this review. | 3 | Alatawi K (2026) | Therapeutic potential of phytochemical compounds in cardiovascular disease: a comprehensive review. |
| Plant Sterols Cholesterol Meta-Analysis | Although more extensive clinical research is needed to determine their long-term efficacy and safety, the evidence now available indicates that phytochemicals may be beneficial supplements to traditional cardiovascular treatments. | 3 | Alatawi K (2026) | Therapeutic potential of phytochemical compounds in cardiovascular disease: a comprehensive review. |
| Plant Sterols Cholesterol Meta-Analysis | Cardiovascular diseases (CVDs) continue to be the world's leading cause of death and a major global healthcare burden. | 3 | Alatawi K (2026) | Therapeutic potential of phytochemical compounds in cardiovascular disease: a comprehensive review. |
| Plant Sterols Cholesterol Meta-Analysis | Concerns about side effects and long-term therapy restrictions have raised interest in supplementary therapeutic approaches, even if traditional pharmaceutical and surgical procedures are still crucial to the management of CVD. | 3 | Alatawi K (2026) | Therapeutic potential of phytochemical compounds in cardiovascular disease: a comprehensive review. |
| Plant Sterols Cholesterol Meta-Analysis | Dyslipidemias, particularly those associated with an increase in the circulating burden of atherogenic apolipoprotein (Apo) B-containing lipoproteins, such as hypercholesterolemia (elevated total cholesterol and low-density lipoprotein cholesterol [LDL-C]), hypertriglyceridemia (elevated triglycerides [TG]), and mixed dyslipidemia (elevated LDL-C and TG), are well-established ASCVD risk factors [,,]. | 3 | Maki Kevin C. (2026) | Effects of Dietary Protein Quantity, Source, and Type on Plasma Lipids and Lipoproteins and Their Roles in Dyslipidemia Management in Humans |
| Plant Sterols Cholesterol Meta-Analysis | LDL-C and non-high-density lipoprotein cholesterol (non-HDL-C), which is calculated as the concentration of total cholesterol minus the concentration of high-density lipoprotein cholesterol (HDL-C) and is a comprehensive measurement of cholesterol carried by all Apo B-containing lipoproteins, are the targets for therapies to lower ASCVD risk []. | 3 | Maki Kevin C. (2026) | Effects of Dietary Protein Quantity, Source, and Type on Plasma Lipids and Lipoproteins and Their Roles in Dyslipidemia Management in Humans |
| Plant Sterols Cholesterol Meta-Analysis | Changes in both have been shown to predict changes in risk, and these relationships are believed to reflect a causal association of the burden of atherogenic lipoprotein particles with the initiation and progression of ASCVD. | 3 | Maki Kevin C. (2026) | Effects of Dietary Protein Quantity, Source, and Type on Plasma Lipids and Lipoproteins and Their Roles in Dyslipidemia Management in Humans |
| Plant Sterols Cholesterol Meta-Analysis | 1 1 2 3 4 5 6 Atherosclerotic cardiovascular disease (ASCVD) is one of the leading causes of death worldwide []. | 3 | Maki Kevin C. (2026) | Effects of Dietary Protein Quantity, Source, and Type on Plasma Lipids and Lipoproteins and Their Roles in Dyslipidemia Management in Humans |
| Plant Sterols Cholesterol Meta-Analysis | So, maintaining low levels of LDL-c over time, following the emerging scientific consensus of ‘lower is better, and earlier is better’, could lead to a substantial reduction in ASCVD risk []. | 3 | Ferrandino Martina (2026) | Genetic Influence on LDL-Cholesterol Levels: Role of Polygenic Risk Scores and Lp(a) Beyond Monogenic Hypercholesterolemia |
| Plant Sterols Cholesterol Meta-Analysis | The aim of this narrative review is to provide an updated overview of the complex genetic architecture underlying hypercholesterolemia and increased cardiovascular risk by discussing the contribution of monogenic disorders, polygenic risk scores (PRS) and lipoprotein(a)—Lp(a)—to increased LDL-c levels (). | 3 | Ferrandino Martina (2026) | Genetic Influence on LDL-Cholesterol Levels: Role of Polygenic Risk Scores and Lp(a) Beyond Monogenic Hypercholesterolemia |
| Plant Sterols Cholesterol Meta-Analysis | This could lead to improved cardiovascular prevention with a more comprehensive and individualized approach and, consequently, better patient management. | 3 | Ferrandino Martina (2026) | Genetic Influence on LDL-Cholesterol Levels: Role of Polygenic Risk Scores and Lp(a) Beyond Monogenic Hypercholesterolemia |
| Plant Sterols Cholesterol Meta-Analysis | 1 2 Figure 1 Atherosclerotic cardiovascular disease (ASCVD) is the main cause of mortality worldwide, with low-density lipoprotein cholesterol (LDL-c) as the main driver of its pathogenesis []. | 3 | Ferrandino Martina (2026) | Genetic Influence on LDL-Cholesterol Levels: Role of Polygenic Risk Scores and Lp(a) Beyond Monogenic Hypercholesterolemia |
Source documents